Vizimpro is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Dacomitinib.
| Product ID | 0069-0197_470f74a3-f9ef-4a24-9bcd-aa54a3538ea9 |
| NDC | 0069-0197 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Vizimpro |
| Generic Name | Dacomitinib |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-10-04 |
| Marketing Category | NDA / NDA |
| Application Number | NDA211288 |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | DACOMITINIB |
| Active Ingredient Strength | 15 mg/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2018-10-04 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA211288 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2018-10-04 |
| Ingredient | Strength |
|---|---|
| DACOMITINIB | 15 mg/1 |
| SPL SET ID: | 4ab27d2f-e385-4e9c-b324-fa69c10b855a |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0069-0197 | Vizimpro | dacomitinib |
| 0069-1198 | Vizimpro | dacomitinib |
| 0069-2299 | Vizimpro | dacomitinib |
| 63539-197 | Vizimpro | dacomitinib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() VIZIMPRO 85979594 4401809 Live/Registered |
Pfizer Inc. 2010-12-08 |
![]() VIZIMPRO 85193224 not registered Dead/Abandoned |
PF PRISM C.V. 2010-12-08 |
![]() VIZIMPRO 77235981 not registered Dead/Abandoned |
Pfizer Inc. 2007-07-23 |